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Abstract
Study Objective—To identify predictors of medication-related problems (MRPs) among 
Medicaid patients participating in a telephonic medication therapy management (MTM) program.
Design—Retrospective analysis of data from patients enrolled in a previously published study
Data Sources—Two Medicaid administrative claims file databases (for healthcare utilization 
and prescription dispensing information) and one pharmacy organization file for MTM program 
information.
Patients—Seven hundred twelve adult Medicaid patients who participated in a statewide 
pharmacist-provided telephone-based MTM program and who received an initial medication 
therapy review.
Measurements and Main Results—The primary dependent variable was the number of 
MRPs detected during the initial medication therapy review. Secondary dependent variables were 
the detection of one or more MRPs related to indication, effectiveness, safety, and adherence. 
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Predictor variables were selected a priori that, from the literature and our own practice 
experiences, were hypothesized as being potentially associated with MRPs: demographics, 
comorbidities, medication use, and healthcare utilization. Bivariate analyses were performed, and 
multivariable models were constructed. All predictor variables with significant associations 
(defined a priori as p<0.1) with the median number of MRPs detected were then entered into a 
three-block multiple linear regression model. The overall model was significant (p<0.001, R2= 
0.064). Significant predictors of any MRPs (p<0.05) were total number of medications, obesity, 
dyslipidemia, and one or more emergency department visits in the past 3 months. For indication-
related MRPs, the model was significant (p<0.001, R2= 0.049), and predictors included female 
sex, obesity, dyslipidemia, and total number of medications (p<0.05). For effectiveness-related 
MRPs, the model was significant (p<0.001, R2= 0.054), and predictors included bone disease and 
dyslipidemia (p<0.05). For safety-related MRPs, the model was significant (p<0.001, R2= 0.046), 
and dyslipidemia was a predictor (p<0.05). No significant predictors of adherence-related MRPs 
were identified.
Conclusion—This analysis supports the relative importance of number of medications as a 
predictor of MRPs in the Medicaid population and identifies other predictors. However, given the 
models’ low R2 values, these findings indicate that other unknown factors are clearly important 
and that criteria commonly used for determining MTM eligibility may be inadequate in identifying 
appropriate patients for MTM in a Medicaid population.
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Introduction
The 2006 implementation of the Medicare Prescription Drug, Improvement, and 
Modernization Act introduced the concept of medication therapy management (MTM) 
services into the Medicare program as part of the new Medicare Part D benefit providing 
outpatient prescription drug insurance to Medicare beneficiaries.1 Since then, stakeholders 
have engaged in numerous conversations regarding delivery models and standards of care 
for conducting MTM. Among other milestones, this has resulted in the development of a 
pharmacy professionwide consensus definition for MTM,2 a description of MTM service 
core elements,3 ongoing modifications to Medicare Part D MTM requirements, and a 
notable increase in MTM-related published literature.4
Since its inception, one of the “hot topics” surrounding MTM has been the criteria used to 
determine patient eligibility for these services. With the implementation of the Medicare 
Part D MTM requirement in 2006, prescription drug plans selected the following eligibility 
criteria for their plan’s MTM program within the broad Medicare requirements: multiple 
chronic diseases, taking multiple covered Part D drugs, and likely to incur annual drug costs 
for covered Part D drugs exceeding approximately $4000.1 As more information about 
MTM has emerged over the last several years, these criteria have been further refined. As of 
2014, these criteria specify that plans can require that patients have two or three comorbid 
conditions to be eligible for MTM, and if they choose to target specific conditions, they 
must target at least five out of nine specific comorbidities. Furthermore, plans can require 
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between two and eight Part D–covered medications, and the cost threshold for eligibility of 
MTM services has been lowered to an approximate annual expenditure of at least $3000.5
Results of MTM program evaluations have been mixed.6–17 Carefully examining patient 
eligibility is an important consideration in optimizing the outcomes of MTM services and 
maximizing the return on investment realized. One strategy is to prospectively identify what 
characteristics predict medication-related problems (MRPs) and then target individuals with 
those characteristics for MTM services. Previous studies have examined predictors of MRPs 
and have used these predictors in the development of a variety of risk assessment tools 
designed to predict a patient’s risk for MRPs.18–27 Examples of previously identified 
predictors include number of medications, number of doses needed/day, number of 
comorbidities, and number of providers prescribing medication.18,23 Although MTM is a 
required benefit for Medicare Part D plans, the provision of MTM by state Medicaid 
programs is becoming more common.28 In previous studies specifically examining MRPs in 
a Medicaid population, the number of medications taken by the patient was found to be an 
important predictor of problems.29–31
Stakeholders, however, have continued to question the value of current Medicare Part D 
eligibility criteria,32–35 and the Centers for Medicare and Medicaid Services is currently 
considering significant changes to these criteria.36 Further evaluation of predictors of MRPs 
and, subsequently, MTM eligibility criteria is warranted among both Medicare beneficiaries 
and other populations.
In this study, we analyzed data from a previously published study on the implementation of 
a statewide telephonic MTM program for Medicaid patients,37 as that study provided an 
opportunity to evaluate MRP predictors in the Medicaid population. Therefore, our objective 
was to identify predictors of MRPs—first by examining MRP predictors across all problem 
categories and second by examining each category of MRPs separately. This work could 
further inform the development of MTM service eligibility, particularly among Medicaid 
beneficiaries.
Methods
Study Design, Patient Population, and Data Sources
This was a retrospective analysis of data collected from adult (aged 18–65) Medicaid 
patients who participated in a statewide pharmacist-provided telephonic MTM program.37 
This MTM program was offered to patients who were enrolled in a specific Medicaid 
program that focused on providing disease management services for chronic conditions 
among the aged, blind, and disabled. The MTM program was optional and offered at no 
additional charge to the member; eligibility criteria included the following: enrollment in the 
Medicaid disease management program, continuous eligibility for Medicaid through the start 
of the MTM program, and receiving at least five Medicaid-covered medications.
In addition to MTM services, the program included medication synchronization and home 
delivery of medications (28-day supply at a time) using specialized packaging to promote 
adherence. As part of the MTM service, patients were telephoned by the pharmacist for an 
Snyder et al. Page 3
Pharmacotherapy. Author manuscript; available in PMC 2015 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
initial medication therapy review (MTR) within the first two months of receiving their 
medications. Follow-up MTM telephone calls occurred as needed. During the initial MTR, 
all medications were reviewed with the patient and caregiver to identify MRPs within four 
broad categories—indication, effectiveness, safety, and adherence, based on the taxonomy 
described by Cipolle et al.38 The pharmacist also prepared a personal medication record and 
a medication-related action plan for the patient. To evaluate the impact of the program on 
medication adherence and healthcare utilization, patients eligible for MTM who opted to 
participate in the service were compared with those who were eligible but opted not to 
participate, and both groups were followed for 12 months.
For this analysis, all patients who received the initial MTR were included. Data were 
extracted from two Medicaid administrative claims files for healthcare utilization and 
prescription dispensing information, and one pharmacy organization file for MTM program 
information. This project was approved by the Indiana University Institutional Review 
Board.
Outcome Measures and Data Analysis
Our primary objective was to identify associations between certain patient characteristics 
and the presence of MRPs. For this analysis, the dependent variable was the number of 
MRPs detected by the pharmacist during the initial MTR. Our secondary objective was to 
identify associations between certain patient characteristics and the presence of MRPs in 
select categories. The dependent variables for this analysis included the detection of one or 
more MRPs (Table 1) related to each type of broad medication problem: indication, 
effectiveness, safety, and adherence. From the available databases, predictor variables were 
selected a priori that, from the literature18,23 and our own practice experiences, were 
hypothesized as being potentially associated with MRPs. Predictor variables (Table 1) 
included patient demographics, comorbidities, medication use data, and healthcare 
utilization. The list of narrow therapeutic index (NTI) drugs was used as it has been 
referenced in previous studies.18 When applicable, comorbidities were defined by using the 
Elixhauser criteria,39 and an overall Elixhauser score was calculated for each patient. In 
addition to select comorbidities included from the Elixhauser criteria, we included 
conditions targeted by the Centers for Medicare and Medicaid Services for eligibility for 
Medicare Part D MTM services.5 However, we excluded Alzheimer’s disease because it is 
not prevalent in this population. The three-month time frame for medication and healthcare 
utilization variables was selected in an effort to characterize medications currently being 
used by the patient. Post hoc predictor variables considered were marital status and location 
of residence. Analyses were conducted by using SPSS, version 20.01 (IBM, Somers, NY), 
and SAS, version 9.2 (SAS Institute Inc., Cary, NC).
We examined each predictor variable independently by using bivariate tests for associations 
with the median number of MRPs detected by the pharmacist during the initial MTR: 
Spearman correlations were used for continuous predictor variables, and Wilcoxon rank sum 
tests were used for categorical predictor variables. The median, rather than mean, number of 
problems was used as our outcome because the problem count was not normally distributed. 
For completeness, we also examined associations between predictor variables and MRPs 
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dichotomized as one or more MRPs were detected by using Student’s t tests or Wilcoxon 
rank sum tests (for nonnormally distributed data) or the Fisher exact analysis for continuous 
and categorical predictor variables, respectively (Table 2.)
All predictor variables with significant associations (defined a-priori as p<0.1) with the 
median number of MRPs detected were then entered into a three-block multiple linear 
regression model. First, the total number of medications was entered, as this variable was 
previously reported to predict MRPs among Medicaid patients.29–31 Then, the other a priori 
variables with significant associations from the bivariate tests were entered to evaluate the 
change in R2. Finally, post hoc variables with significant associations from the bivariate 
tests were entered.
We also conducted sensitivity analyses for the primary outcome by examining predictor 
variables for associations with the number of MRPs at different thresholds (≥ 10, ≥ 20, ≥ 30, 
or ≥ 40 MRPs). Predictor variables with a resulting p value of < 0.1 on the bivariate tests 
described above were entered into a logistic regression model. The dependent categorical 
variable was the presence or absence of the defined threshold level of MRPs.
For the secondary objective, we examined each predictor variable independently for 
associations with whether one or more MRP was present for each broad category of MRPs 
(indication, effectiveness, safety, adherence).38 All predictor variables with p values of < 
0.1, as identified by using Student’s t-tests or Wilcoxon rank sum tests (for nonnormally 
distributed data) or the Fisher exact analysis for continuous and categorical predictor 
variables, respectively, were entered into four separate logistic regression models. For each 
regression model, the dependent categorical variable was the presence of at least one MRP 
in the category under consideration. No cases were deleted from any of the regression 
analyses, and no data were missing for any of the variables.
Results
A total of 712 patients received an initial MTR and were included in this analysis. The 
sample consisted primarily of Caucasian women, approximately 50 years of age, with an 
average of two comorbidities, and using an average of 11 medications (Table 2). Sixty-one 
percent of patients (Figure 1) had one or more MRPs identified (median 11, interquartile 
range [25th–75th percentile] 0–28 MRPs). Patients with one or more MRPs were more 
likely to be obese and have one or more visits to emergency department (ED), and less likely 
to be diagnosed with depression, compared to those patients without an MRP. The following 
predictor variables were significant (p<0.1) on bivariate tests and entered into the 
multivariate linear regression model for the primary outcome: female sex, race, 
dyslipidemia, obesity, one or more ED visits, number of chronic medications, and total 
number of medications. The overall model was significant (p < 0.001, R2= 0.064). 
Significant predictors of MRPs (p < 0.05, Table 3) included dyslipidemia, obesity, one or 
more ED visits, and total number of medications. Post hoc predictor variables were 
evaluated as bivariate tests to determine whether social support (i.e., marital status and 
access to services) could explain these findings. Location of residence was significant (p= 
0.041) and was entered as a third block to the regression model. The adjusted R2 value was 
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unchanged. Collinearity statistics in the stepwise multiple regression were satisfactory (i.e., 
tolerance statistics > 0.1), although there was a trend toward collinearity for number of 
chronic medications (tolerance statistic= 0.297.) In sensitivity analyses for 10, 20, 30, and 
40 or more MRPs/patient (Table 4), all variables remained significant predictors in the 
models except for ED visits.
With regard to specific problem types, predictors of indication, effectiveness, and safety-
related problems are summarized in Table 5. No significant predictors of adherence-related 
MRPs were identified through bivariate tests; therefore, no multivariable model was 
evaluated.
Discussion
This work expands current knowledge of MRP predictors, particularly within the context of 
MTM services. Although Medicare Part D MTM is provided by pharmacists nationally, it is 
increasingly common for Medicaid programs to provide these services as a covered benefit, 
and these findings are especially relevant for those stakeholders.28 We identified significant 
predictors of MRPs in a Medicaid population receiving MTM, both for MRPs in general and 
for the categories of MRPs related to indication, effectiveness, and safety. Significant 
predictors of adherence-specific problems were not identified in this analysis. This may be 
due to the smaller overall prevalence of these problems in this sample compared to other 
problem types. This sample may have experienced fewer adherence problems than a typical 
sample receiving MTM, as the program also included special packaging to promote 
medication adherence. More research to identify predictors of adherence-related problems 
identified by pharmacists in the course of MTM, particularly among Medicaid patients, is 
needed.
Furthermore, more research concerning predictors of any MRPs identified in patients 
receiving MTM is needed. As the outcomes of MTM program evaluations have varied,6–17 
one way in which outcomes may be improved is through better targeting of patients who 
would be likely to benefit from these services. The provision of high-quality MTM is likely 
to be time consuming for pharmacists; thus, mechanisms that enable the careful selection of 
patients who should receive MTM may promote more efficient resource allocation and 
improved service outcomes.
Although we did identify predictors in statistically significant regression models, our models 
explained very little of the overall variability (as evidenced by a small R2 values for each 
model) in MRPs experienced by patients receiving the service. This is concerning, as our 
models included variables commonly used in determining eligibility for MTM. However, 
patient medication cost is another variable that is commonly used for determining eligibility, 
but our models did not evaluate this variable. Clearly, additional variables should be 
considered as playing an important role in MRP variability. Variables to consider include 
those measuring social support (other than marital status), transportation barriers other than 
location of residence based on ZIP code, and patient health literacy, medication beliefs, and 
knowledge and satisfaction pertaining to their medications.
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This work suggests an opportunity for enhancing eligibility criteria in order to optimize the 
outcomes of pharmacist-provided MTM. A patient history of one or more visits to the 
emergency department in the past three months was a predictor of overall MRPs. A visit to 
the emergency department may result in the addition of new medications or changes in 
medications, prompting a need for a comprehensive medication review to resolve 
duplication in therapies, drug-drug interactions, or other problems. Using this as a criterion 
for MTM eligibility could be considered by insurers managing both prescription and 
medical services.
Considering the presence of specific comorbidities also appears to add value. Dyslipidemia 
was consistently identified in our models as a predictor. One potential explanation could be 
that statin medications are commonly used for dyslipidemia and are commonly prescribed 
overall.40 Although generally well tolerated, adverse effects do occur, as does prescribing 
inertia.41–44 Because of these challenges with statin therapy, pharmacists may have found 
opportunities for dose optimization and adverse-effect resolution, resulting in associations 
between dyslipidemia and specific problem types (i.e., indication, effectiveness, and safety) 
as well as overall MRPs. Obesity was also a significant predictor of problems overall. In 
further examining obesity in this sample, we found that obese patients had more 
comorbidities than nonobese patients, and obesity was associated with diabetes mellitus, 
hypertension, heart failure, and other comorbidities. Therefore, although the presence of 
some of these comorbidities alone did not predict problems, obese patients may represent 
more complex patients overall, resulting in a greater risk for MRPs. Interestingly, we did not 
find an association between obesity and dyslipidemia even though both were predictors. 
Therefore, targeting patients with obesity and/or dyslipidemia for MTM could be a useful 
strategy for optimizing MTM outcomes.
Previous studies of MRP predictors in Medicaid patients have identified the number of 
medications as an important predictor. Specifically, Alkema et al. found that number of 
medications was a significant predictor of MRPs in an older, dually eligible, Medicaid 
sample (odds ratio [OR] 1.183, 95% confidence interval [CI] 1.13–1.24), although MRPs 
were defined by using a different classification system31. Similarly, Bain et al. found the 
number of medications to be an important MRP predictor (OR 4.17, 95% CI 2.48–7.00) in 
an older, frail Medicaid sample.29 Finally, McGhan et al. identified the number of 
medications as an MRP predictor in Medicaid patients in the 1970s.30 Specifically, for every 
additional medication that a patient was taking, there was a 0.25-increase in the “need for 
pharmacist to monitor patient’s drug therapy” as measured on a scale from 1 to 5. In our 
sample, the number of medications was also a predictor of MRPs overall, and this reflects 
current Medicare Part D MTM eligibility criteria; however, some of the other predictors 
identified may warrant greater attention. Specifically, although our model identified number 
of medications as a significant predictor, the number of medications did not distinguish 
between patients without MRPs and patients having at least one MRP. Rather, the 
relationship between number of medications and MRPs appears to be linear, with more 
medications resulting in more MRPs identified. This finding supports previous literature.45
Other predictors that we identified differ somewhat from those identified previously in 
Medicaid patients. The Alkema,31 Bain,29 and McGhan30 studies all found age to be a 
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predictor of MRPs; however, the associations were fairly modest (e.g., OR 1.029, 95% CI 
1.01–1.05 in the Alkema study31), which may partially explain why age was not identified 
as a predictor in our models. In contrast, female sex was identified in the McGhan study to 
be a predictor30 and was also a predictive variable in our analyses.
Nevertheless, our analyses resulted in some unexpected findings. Specifically, our bivariate 
tests found that depression appears to be associated with fewer MRPs. Although the reason 
for this is unknown, one possibility is that pharmacists were not able to detect as many 
MRPs in these patients. Literature suggests that pharmacists are less confident caring for 
patients with mental health diagnoses, including depression, and that additional training for 
pharmacists is needed to improve the pharmaceutical care of these patients.46–48
There are several limitations to our work. First, several taxonomies for defining MRPs 
exist,46–47 and the results of our analysis may have been influenced by the specific 
taxonomy used by the pharmacists providing the MTM service. The number of MRPs 
reported by pharmacists in this MTM program was higher than that reported previously 
among Medicaid patients29,31 and may be due to differences in how MRPs were identified 
and documented. The pharmacists received one day of training along with supporting 
manuals on the MTM documentation system and clinical thought processes for MRP 
identification, using materials developed by the company providing the commercially 
available MTM documentation platform. The MRP documentation process and MTM 
approach used by the company is well described.38 However, the extent to which the 
pharmacists documented problem categories similarly or differently is unknown, particularly 
given that multiple pharmacists provided the MTM service. In addition, given that our 
analyses were based on data from a retrospective cohort study that evaluated the MTM 
program, the extent to which the MTM program conducted quality assurance checks to 
determine the quality of MRP documentation and authenticity of identified MRPs is 
unknown. Therefore, the influence of inadequate or inappropriate MRP documentation on 
our outcomes is unknown. Additionally, our data source included only Medicaid claims for 
medications; therefore, medications that patients may have received from other sources were 
not included in our calculations. Furthermore, the definition of our outcome measure (i.e., 
MRPs as documented by the pharmacist) may have impacted our findings. Our findings 
could have been different had the service been provided by another provider type (e.g., a 
nurse) or if the outcome would have been defined differently (e.g., adverse drug event 
requiring hospitalization with an accompanying diagnosis code.) These findings could 
change according to the modality used for delivery of the MTM intervention. As 
pharmacists in this MTM program provided the service and identified MRPs by telephone, 
different or additional MRPs may have been detected had the service been provided face to 
face. An evaluation of a different telephonic MTM program found that the program was 
effective for a subset of, but not all, patients and may be related to the modality used to 
deliver MTM.51 Other research has found that MTM services provided by community 
pharmacists (whether by telephone or face to face) resulted in a greater reduction in drug use 
and associated drug costs compared to MTM provided by call center pharmacists52; 
however, the role that the telephone versus a preexisting relationship between the pharmacist 
and patient may play in MRP detection is unclear. It is also important to note the limitations 
of our sample. As we examined data from individuals participating in an MTM program, we 
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are limited by the eligibility criteria initially used for the service. In this case, the program 
was available for patients enrolled in the state Medicaid care management program who 
were taking five or more medications and with one or more specific chronic diseases. 
Finally, as this was a Medicaid population, our ability to generalize these findings to all 
patients receiving MTM, particularly Medicare Part D, is limited.
Conclusion
This work supports the relative importance of the number of medications as a predictor of 
MRPs in the Medicaid population and identifies other MRP predictors such as the number of 
recent ED visits and comorbid obesity for providers and policymakers to consider when 
developing MTM eligibility criteria. However, these findings indicate that other unknown 
factors are clearly important in understanding patient risk for MRPs. Criteria commonly 
used for determining MTM eligibility may be inadequate in identifying appropriate patients 
for MTM in a Medicaid population. Future studies examining other types of predictor 
variables (e.g., transportation barriers, social support variables, patient health literacy, and 
medication beliefs) may fill a gap in the literature and further explain variability among 
MRPs.
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Figure 1. 
Prevalence of medication-related problems (MRPs) detected in the 172 patients.
Snyder et al. Page 13
Pharmacotherapy. Author manuscript; available in PMC 2015 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Snyder et al. Page 14
Table 1
Definitions of Variables
Variable Definition/Comments
Predictors
Patient Demographics
Age Continuous, from 18–65 yrs
Sex
Race Dichotomized to Caucasian vs other
Urban vs rural residence Dichotomized by using patient’s ZIP code of residence
Marital status (married vs not 
married)
Dichotomized as married or not married
Comorbidities
Hypertension Determined by all ICD-9 codes in the Medicaid database 1 year prior to first MTM telephone call using 
Elixhauser criteria39
Chronic lung disease
Diabetes mellitus
Obesity
Depression
Heart Failure
Renal failure
Liver disease
Alcohol abuse
Drug abuse
Psychoses
Bone disease (includes 
osteoporosis, osteoarthrosis, allied 
disorders, and rheumatoid 
arthritis)
Determined by all ICD-9 codes in the Medicaid database 1 year prior to first MTM telephone call using 
ICD-9 codes recognized as codes for disease states targeted for MTM by CMS. Specific codes included: 
V17.81 Osteoporosis; V82.81 Osteoporosis; 733.00 Osteoporosis, unspecified; 715 Osteoarthrosis and 
allied disorders (arthritis or polyarthritis, degenerative, hypertrophic, degenerative joint disease, 
osteoarthritis); 714.0 Rheumatoid arthritis V82.1 Rheumatoid arthritis
Dyslipidemia Determined by all ICD-9 codes in the Medicaid database 1 year prior to first MTM telephone call using 
ICD-9 codes recognized as codes for disease states targeted for MTM by CMS. Specific codes included: 
272.0 pure hypercholesterolemia; 272.2 hyperlipidemia, mixed; 272.4 hyperlipidemia, other
Total no. of comorbidities Sum of each comorbidity present using Elixhauser criteria39
Medication Use Data
No. of pharmacies Calculated from Medicaid medication reimbursement records 3 months prior to MTR
No. of prescribers
No. of chronic medications Calculated as no. of unique scheduled oral medications for 3 months prior to MTR
No. of pills/day
Total no. of medications Calculated from all medication records 3 months prior to MTR; all medications and dosage forms 
included
No. of narrow therapeutic index 
drugs
Calculated from all medication records 3 months prior to MTR; all medications and dosage forms 
included
Narrow therapeutic index drugs included carbamezepine, lithium, phenytoin, quinidine, warfarin, 
phenobarbital, procainamide, theophylline, digoxin, and insulin
Healthcare Utilization
No. of outpatient visits Calculated by using Medicaid claims data for 3 months prior to MTR
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Variable Definition/Comments
No. of patients with ≥ 1 
hospitalization
No. of patients with ≥ 1 ED visit
Outcomes
Primary
No. of MRPs detected Data from initial MTR only; includes all problem categories
Secondary
At least one MRP in indication 
category
Data from initial MTR only. Problems included were untreated condition, synergistic therapy, 
preventative therapy (collapsed into “needs additional therapy”); no medical indication, recreational 
drug, nondrug therapy, duplicate, treating avoidable adverse reaction (collapsed into “unnecessary drug 
therapy”)
At least one MRP in effectiveness 
category
Data from initial MTR only. Problems included dosage form inappropriate, contraindication, condition 
refractory to drug, not indicated, more effective drug (collapsed into “different drug needed”); 
ineffective, inappropriate frequency, duration, storage, administration (collapsed into “dosage too low”)
At least one MRP in safety 
category
Data from initial MTR only. Problems included unsafe, allergic reaction, undesired effect, interaction, 
dosage changed too fast (collapsed into “adverse drug reaction”); dose too high, frequency too short, 
duration too long (collapsed into “dosage too high”); drug interaction resulting in dose too high/low, 
needs additional monitoring (collapsed into “dosage too high/low”)
At least one MRP in adherence 
category
Data from initial MTR only. Problems included not available, cannot afford, cannot administer, forgets, 
does not understand, prefers not to take (collapsed into “noncompliance”)
ICD = International Classification of Diseases, Ninth Revision; MRP = medication-related problem.
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Table 2
Demographic and Clinical Characteristics of the Study Patients
Characteristic All Patients
(n=712)
Patients
without
MRPs
(n=277)
Patients with ≥
1 MRP (n=435)
p-
valuea
Age (yrs) 50.2 +/− 8.6 50 +/− 9.7 50.4 +/− 7.9 0.601
Female sex 520 (73) 191 (69) 329 (75.6) 0.057
Caucasian 577 (81) 233 (84.1) 344 (79.1) 0.097
Married 141 (19.8) 52 (18.8) 89 (20.5) 0.630
Urban residence 379 (53.2) 138 (49.8) 241 (55.4) 0.166
Hypertension 358 (50.3) 139 (50.2) 219 (50.3) 1.0
Chronic lung disease 230 (32.3) 86 (31) 144 (33.1) 0.622
Diabetes mellitus 278 (39) 107 (38.6) 171 (39.1) 0.935
Depression 80 (11.2) 40 (14.4) 40 (9.2) 0.038
Psychoses 64 (9) 25 (9) 39 (9) 1.0
Bone disease 232 (32.6) 91 (32.9) 141 (32.4) 0.935
Dyslipidemia 371 (52.1) 133 (48) 238 (54.7) 0.091
End-stage renal disease 25 (3.5) 8 (2.9) 17 (3.9) 0.536
Heart failure 69 (9.7) 28 (10.1) 41 (9.4) 0.796
Obesity 89 (13) 25 (9) 64 (14.7) 0.027
Liver disease 27 (3.8) 9 (3.2) 18 (4.1) 0.688
Alcohol abuse 19 (2.7) 8 (2.9) 11 (2.5) 0.814
Drug abuse 36 (5.1) 22 (7.9) 14 (3.2) 0.108
Total no. of comorbiditiesb 2.5 +/− 2.1 2.5 (2.1) 2.5 (2.0) 0.675
No. of pharmacies 2.9 +/− 1.9 2.8 (1.8) 3 (1.9) 0.134
No. of prescribers 1.2 +/− 0.6 1.2 (0.7) 1.3 (0.6) 0.568
No. of chronic medications 5.6 +/− 3.0 5.4 (3) 5.7 (3) 0.268
Total no. of medications 10.6 +/−5.4 10.2 (5.4) 10.8 (5.4) 0.128
No. of narrow therapeutic index medications 0 (0–2) 0 (0–0) 0 (0–0) 0.702
No. of pills/day 17.3 (10–28.5) 18 (9–28) 17 (10–29.9) 0.582
No. of outpatient visits in the past 3 mo 2 (0–2) 1 (0–2) 2 (0–3) 0.396
Had ≥ 1 hospitalization in the past 3 mo 120 (16.8) 49 (17.7) 71 (16.1) 0.607
Had ≥ 1 emergency department visit in the past 3 mo 479 (67.3) 174 (62.8) 305 (70.1) 0.049
Data are mean ± SD, no. (%) of patients, or median (interquartile range [25th–75th percentile]).
a
: For the comparison between patients with one or more MRPs vs patients without MRPs; data were analyzed by using Student’s t tests or 
Wilcoxon rank sum tests (for nonnormally distributed data) or the Fisher exact analysis for continuous and categorical predictor variables, 
respectively.
b
: Calculated by using the Elixhauser criteria39
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Table 4
Sensitivity Analyses for the Primary Outcome
Dependent
Variable
Significant Predictorse P-value Parameter
Estimate of B
Odds Ratio (95%
Confidence Interval)
≥ 10 MRPsa Female sex 0.017 −0.445 0.641 (0.444–0.924)
Dyslipidemia 0.001 0.546 1.726 (1.243–2.397)
Obesity 0.011 0.605 1.831 (1.150–2.918)
≥ 20 MRPsb Female sex 0.017 −0.445 0.641 (0.444–0.924)
Dyslipidemia 0.001 0.546 1.726 (1.243–2.397)
Obesity 0.011 0.605 1.831 (1.150–2.918)
≥ 30 MRPsc Total no. of medications 0.005 0.078 1.081 (1.024–1.141)
No. of chronic medications 0.020 −0.118 0.889 (0.805–0.981)
Dyslipidemia 0.001 0.573 1.773 (1.252–2.512)
Obesity 0.006 0.664 1.942 (1.209–3.119)
≥ 40 MRPsd Total no. of medications 0.014 0.074 1.077 (1.015–1.142)
Rural residence 0.018 0.450 1.568 (1.080–2.275)
Dyslipidemia < 0.001 0.836 2.308 (1.555–3.426)
Obesity 0.036 0.547 1.728 (1.035–2.884)
a
: Overall model, p < 0.001, R2= 0.068
b
: Overall model, p < 0.001, R2= 0.068
c
: Overall model, p < 0.001, R2= 0.073
d
: Overall model, p < 0.001, R2= 0.088
e
: Variables entered in all models: total no. of medications, sex, race, obesity, dyslipidemia, no. of chronic medications, one or more ED visits, and 
place of residence (rural vs urban)
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Table 5
Predictors of Medication-Related Problems by Problem Typea
Dependent Variable Significant Predictors P-value Parameter
Estimate
of B
Odds Ratio (95%
Confidence
Interval)
One or more indication-related problemsb Female sex 0.008 –0.341 1.641 (1.140– 2.372)
Dyslipidemia 0.001 0.491 1.724 (1.244– 2.400)
Obesity 0.004 0.541 1.643 (1.030– 2.635)
Total no. of medications 0.015 0.017 1.071 (1.010– 1.130)
One or more effectiveness-related problemsc Dyslipidemia 0.002 0.558 1.684 (1.211– 2.310)
Bone disease 0.033 0.327 1.433 (1.211– 2.311)
One or more safety-related problemsd Dyslipidemia <0.001 0.695 2.003 (1.460– 2.747)
a
: No significant predictors of adherence-related problems were identified on bivariate analyses; therefore, no model was evaluated.
b
: Overall model, p < 0.001, R2= 0.049. Variables also included were race, depression, no. of chronic medications, and no. of pills per day. 
Specific problems included in this category were untreated condition, synergistic therapy, preventative therapy, no medical indication, recreational 
drug, nondrug therapy, duplicate, and treating avoidable adverse reaction
c
: Overall model, p < 0.001, R2= 0.054. Variables also included were sex, obesity, no. of pharmacies, no. of chronic medications, no. of pills per 
day, and total no. of medications. Specific problems included in this category were dosage form inappropriate, contraindication, condition 
refractory to drug, not indicated, more effective drug, ineffective, inappropriate frequency, duration, storage, and administration
d
: Overall model, p < 0.001, R2= 0.046 Variables also included were no. of pills per day and no. of outpatient visits. Specific problems included in 
this category were unsafe, allergic reaction, undesired effect, interaction, dosage changed too fast, dose too high, frequency too short, duration too 
long, drug Interaction resulting in dose too high or low, and needs additional monitoring
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